Guo-ying Liu
651 Dongfeng East Road
Guangzhou, 510060, China
Guangzhou, 510060, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Induction Paclitaxel-Cisplatin-Capecitabine for Nasopharyngeal Carcinoma.
Journal: NEJM evidence
Published: August 25, 2026
Efficacy of radiotherapy to metastatic lesion in de novo metastatic nasopharyngeal carcinoma patients: A multicenter, propensity score matching study.
Journal: Oral oncology
Published: December 14, 2025
Efficacy of metastatic lesion radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving local regional radiotherapy and chemo-immunotherapy: a multicenter retrospective study.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: June 24, 2025
Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study.
Journal: Oral oncology
Published: August 17, 2024
Efficacy of local-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: August 17, 2024
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial.
Journal: BMJ (Clinical research ed.)
Published: June 19, 2024
Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial.
Journal: Nature communications
Published: August 28, 2023
Association of Socioeconomic Disparities With Nasopharyngeal Carcinoma Survival in an Endemic Area, China.
Journal: Cancer control : journal of the Moffitt Cancer Center
Published: July 31, 2023
Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study.
Journal: EClinicalMedicine
Published: February 15, 2023
Development of a prognostic model to identify the metastatic nasopharyngeal carcinoma patients who may benefit from chemotherapy combination PD-1 inhibitor.
Journal: Frontiers in immunology
Published: October 13, 2022
Capecitabine Maintenance in Metastatic Nasopharyngeal Carcinoma-Reply.
Journal: JAMA oncology
Published: June 30, 2022
Last Updated: 09/26/2026